Narrowing the Gap in Neurodegenerative Drug Development to Meet Regulatory Needs
Time: 2:00 pm
day: Clinical & Commercial Track Day 2 PM
Details:
- Identifying and generating evidence to support safety biomarkers (including fluid and imaging) as clinical endpoints
- Discussing data sharing and generating regulatory-grade data
- Regulatory successes of drug development tools (biomarkers, trial simulation tools, patient enrichment tools) and impact on clinical trials
